Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age

Pfizer264 enrolled

Overview

The purpose of this protocol is to retrospectively study the influence of age at start of growth hormone (GH) treatment on height gain in children born small for gestational age (SGA).

Study Type

OBSERVATIONAL

Enrollment

264

Conditions

Small For Gestational Age (SGA)

Interventions

growth hormoneDRUG

36 months

Eligibility

Sex: ALLMin age: 4 Years

Medical Language ↔ Plain English

Inclusion Criteria: * SGA children. * Treated with GH at least 36 months. Exclusion Criteria: * Patients treated with GH for other indications (not SGA).

Locations (12)

H. Germans Trias i Pujol

Badalona, Barcelona, Spain

Capio H.Universitario Sagrat Cor

Barcelona, Barcelona, Spain

H. Vall d'Hebron

Barcelona, Barcelona, Spain

Outcomes

Primary Outcomes

height SDS

height SDS of SGA children after 36 months of treatment

Time frame: 36 months

Secondary Outcomes

height increase

Time frame: 36 months

Change from Baseline in Lipid Parameters at Month X

Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations.

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.